Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,966 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lipid-free apolipoprotein A-I and discoidal reconstituted high-density lipoproteins differentially inhibit glucose-induced oxidative stress in human macrophages.
Tabet F, Lambert G, Cuesta Torres LF, Hou L, Sotirchos I, Touyz RM, Jenkins AJ, Barter PJ, Rye KA. Tabet F, et al. Among authors: hou l. Arterioscler Thromb Vasc Biol. 2011 May;31(5):1192-200. doi: 10.1161/ATVBAHA.110.222000. Epub 2011 Feb 17. Arterioscler Thromb Vasc Biol. 2011. PMID: 21330603
Apolipoprotein A-I improves pancreatic β-cell function independent of the ATP-binding cassette transporters ABCA1 and ABCG1.
Hou L, Tang S, Wu BJ, Ong KL, Westerterp M, Barter PJ, Cochran BJ, Tabet F, Rye KA. Hou L, et al. FASEB J. 2019 Jul;33(7):8479-8489. doi: 10.1096/fj.201802512RR. Epub 2019 Apr 10. FASEB J. 2019. PMID: 30970222
In summary, apoA-I treatment improves GSIS by a cholesterol-independent mechanism, but it does not correct metabolic dysregulation in beta-DKO mouse islets.-Hou, L., Tang, S., Wu, B. J., Ong, K.-L., Westerterp, M., Barter, P. ...
In summary, apoA-I treatment improves GSIS by a cholesterol-independent mechanism, but it does not correct metabolic dysregulation in beta-D …
Human macrophage cathepsin B-mediated C-terminal cleavage of apolipoprotein A-I at Ser228 severely impairs antiatherogenic capacity.
Dinnes DL, White MY, Kockx M, Traini M, Hsieh V, Kim MJ, Hou L, Jessup W, Rye KA, Thaysen-Andersen M, Cordwell SJ, Kritharides L. Dinnes DL, et al. Among authors: hou l. FASEB J. 2016 Dec;30(12):4239-4255. doi: 10.1096/fj.201600508R. Epub 2016 Sep 14. FASEB J. 2016. PMID: 27630170
Cleavage at Ser(228) is a novel, functionally important post-translational modification of apoA-I mediated by HMDMs that limits the antiatherogenic properties of apoA-I.-Dinnes, D. L. M., White, M. Y., Kockx, M., Traini, M., Hsieh, V., Kim, M.-J., Hou, L., Je …
Cleavage at Ser(228) is a novel, functionally important post-translational modification of apoA-I mediated by HMDMs that limits the antiathe …
5,966 results